Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Net Margin (2017 - 2025)

Historic Net Margin for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to 519.23%.

  • Arcus Biosciences' Net Margin fell 3275600.0% to 519.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 142.08%, marking a year-over-year decrease of 394200.0%. This contributed to the annual value of 109.69% for FY2024, which is 1527000.0% up from last year.
  • Per Arcus Biosciences' latest filing, its Net Margin stood at 519.23% for Q3 2025, which was down 3275600.0% from 400.0% recorded in Q1 2025.
  • In the past 5 years, Arcus Biosciences' Net Margin ranged from a high of 78.83% in Q4 2021 and a low of 824.17% during Q3 2021
  • For the 5-year period, Arcus Biosciences' Net Margin averaged around 339.5%, with its median value being 259.96% (2023).
  • Data for Arcus Biosciences' Net Margin shows a peak YoY increase of 17726800bps (in 2021) and a maximum YoY decrease of -8270000bps (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Arcus Biosciences' Net Margin stood at 78.83% in 2021, then crashed by -350bps to 197.06% in 2022, then tumbled by -33bps to 261.29% in 2023, then plummeted by -38bps to 361.54% in 2024, then crashed by -44bps to 519.23% in 2025.
  • Its last three reported values are 519.23% in Q3 2025, 400.0% for Q1 2025, and 361.54% during Q4 2024.